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Abstract
Due to space requirements and a substantial financial burden, the feasibility of 
health systems adopting proton therapy has been called into question. However, 
advances in facility design and treatment delivery have allowed institutions offering 
proton therapy to reduce footprint while incorporating technological improvements 
at reduced costs. As the number of centers and patients treated continue to increase, 
this chapter will review the layout and interface of proton therapy facilities provid-
ing a detailed overview of the design, costs and faculty and staff considerations.
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1. Introduction
The use of proton radiotherapy in oncology has gained renewed interest in 
recent years. The unique physical properties of protons and potential applications 
in radiation oncology were initially recognized by Robert Wilson in 1946 [1]. 
Soon after, the first patients were treated with proton therapy in the 1950’s at the 
Lawrence Berkeley Laboratory [2]. Throughout the 1950’s to 1970’s, other institu-
tions including the Harvard Cyclotron Laboratory, the Gustaf Werner Institute 
in Uppsala, Sweden and several facilities in Russia pioneered seminal studies 
that provided important insight demonstrating the advantages of proton therapy 
in the treatment of patients with cancers of the brain, eye, head and neck and 
skin [3–17]. This laid the groundwork for the transition of proton facilities from 
research institutes into hospital settings. Loma Linda University Medical Center 
was the first to accomplish this in the 1990’s [18]. Since that time, the number of 
proton therapy centers and patients being treated worldwide has substantially 
increased [19].
As the demand for proton therapy has amplified, several vendors and facili-
ties have attempted to address these needs through the development of new 
technology that reduces dose to surrounding structures. One such example is the 
advent of pencil-beam scanning that limits entry and exit dose to targets of large 
volume while achieving superior conformity when compared to photon therapy 
[20]. Although the use of proton therapy has increased with more centers being 
constructed in the United States and throughout the world, questions remain 
regarding core patient cohorts that will benefit from its use. Moreover, the clinical 
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scenarios where the dose distribution advantages will provide better outcomes are 
still being elucidated [21]. This has led to hospital facilities questioning whether 
these potential benefits outweigh the financial and space requirements of a proton 
therapy center. Vendors have responded by supplying cutting-edge equipment, 
treatment planning systems, variations to existing proton beams and determin-
ing new ways to limit space. This has led to further innovations in proton therapy 
systems and a smoother integration with departments of radiation oncology and 
their existing photon system network.
In light of the continued evolution regarding footprint of proton therapy 
centers, this chapter will discuss facility design and equipment interface in order to 
provide an overview of the applicability of hospital-based proton systems.
2. Vendors
Mevion Medical Systems, IBA (Ion Beam Applications S.A.) Proton Therapy, 
Hitachi and Varian Medical Systems are the major proton therapy manufacturers 
throughout the world. Each vendor offers unique and advantageous proton therapy 
technology that allows health systems to construct a proton facility based on their 
specific requirements.
Mevion Medical Systems has developed many proton facilities throughout the 
United States with the most prominent located at the S. Lee Kling Proton Therapy 
Center at Siteman Cancer Center of Washington University School of Medicine 
and Barnes-Jewish Hospital [22]. Mevion developed the S250 proton accelerator 
system, which is a superconducting synchrocyclotron with a gantry-mounted 
proton source that rotates 190 degrees around the patient to facilitate optimal beam 
access. Specifically, the S250i series incorporates pencil-beam scanning for intensity 
modulated proton therapy by using a low-profile multi-leaf collimator system. For 
high volume proton centers, the S250MX system offers multiple room configura-
tions and independent gantries.
IBA has established itself as an industry leader in proton therapy and has con-
structed numerous facilities throughout the world [23]. The Proteus system by IBA 
is also synchrocyclotron-based with the ability of pencil-beam scanning for inten-
sity modulated proton therapy but incorporates a compact gantry that rotates 360 
degrees around the patient. The general layout of a proteus-based treatment room 
consists of an open treatment enclosure, gantry rolling floor and in-room imaging 
control that, together, is about the size of two linear accelerator vaults. The reduced 
footprint and freedom in treatment plans are highly favorable characteristics for 
both hospital facilities and physicians.
Hitachi is also a leader in proton facility development as evidenced not only by 
the success of the University of Texas MD Anderson Cancer Center, but by several 
centers in Japan [24]. Hitachi offers a low footprint synchrotron with variations in 
gantries, which include full-sized 360-degree, compact 360-degree and 190-degree 
options. The type/s of gantry selected can be constructed into single room or multi-
room designs to deliver intensity modulated proton therapy and real-time image 
gated proton therapy.
The development of the ProBeam 360 by Varian Medical Systems uses a super-
conducting cyclotron and 360-degree gantry to deliver intensity modulated proton 
therapy in single or multiple room configurations [25]. Each vendor offers effective 
technology that limits footprint, which leaves health systems options to determine 
number of treatment rooms, 360 vs. 190-degree gantry angle and if a synchrocyclo-
tron, synchrotron or cyclotron is most appropriate for their needs.
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3. Proton therapy center example-based layout
The design and layout of a proton therapy center is dependent on if it will be a 
part of a larger, hospital-based organization or a stand-alone facility. If a compo-
nent of a radiation oncology department, then it will need to be determined if the 
proton therapy center will be located within the core department along with photon 
therapy equipment or at another location. Treatment rooms to be designed include 
the gantry, beam and control rooms as well as beam line and accelerator vault 
rooms, which include space for experimental setup and storage. As with any radia-
tion oncology treatment facility, procedure rooms, examination rooms, reception 
area and administrative offices will need to be included in the overall layout.
The space requirements for a proton center are dependent on the number and 
size of treatment rooms as well as other medical and patient areas. The University 
of Texas MD Anderson Cancer Center proton facility was the first to be part of a 
National Cancer Institute (NCI)-designated comprehensive cancer center [26]. It is 
comprised of four rooms within a unit that is 96,000 total square feet. This includes 
a single beam room with two fixed horizontal lines, one for large volume targets 
and another for small volume targets (such as structures within the eye) while the 
other three rooms contain isocentric gantries. Proton therapy equipment at MD 
Anderson was acquired through Hitachi and treatment planning occurs through use 
of technology by Varian Medical Systems. Hitachi also developed the proton therapy 
center at St. Jude Children’s Research Hospital, which consists of two rotating 
gantry rooms and one fixed horizontal beam room [27]. Proton therapy has demon-
strated favorable results for several pediatric cancers [28], and this undertaking by 
St. Jude Children’s Research Hospital further demonstrated the clinical importance 
of proton therapy for pediatric patients.
As mentioned above, IBA has constructed some of the largest proton centers in 
the country. The Roberts Proton Therapy Center at Penn Medicine is regarded as 
one of the world’s largest centers, which offers both proton and photon therapy. It 
consists of four gantry rooms, a fixed beam room designated for treating conditions 
of the eye and a research room using the Proteus system by IBA [29] Similarly, the 
University of Florida Proton Therapy Institute is comprised of four gantry rooms 
and one fixed beam room, while the Francis H. Burr Proton Therapy Center at 
Massachusetts General Hospital has a fixed beam room for eye treatments and two 
gantry rooms [30]. Of note, the Francis H. Burr Proton Therapy at Massachusetts 
General Hospital initiated operations in 2002 after transfer from the Harvard 
Cyclotron Laboratory.
Another important example that highlights the versatility of proton facilities is 
the S. Lee Kling Proton Therapy Center at Siteman Cancer Center of Washington 
University School of Medicine and Barnes-Jewish Hospital, which was initiated in 
2013 [31]. This system was the first gantry-mounted cyclotron and, accordingly, the 
first single-room proton center of its kind. The rotating gantry used by this system 
provides a platform for the beam to enter the treatment room from a 190 degree 
angle [31].
In 2020, the S. Lee Kling Proton Therapy Center expanded its operations 
through the addition of the Mevion S250i Proton Therapy System, which was 
installed directly next to the original system. This 1 + 1 expansion has substantial 
implications for limiting space requirements while increasing patient volume and 
delivering more efficient treatments, which incorporates Adaptive Aperture and 
Hyperscan technology. Of note, a collaboration between radiation oncologists at the 
S. Lee Kling Proton Therapy Center and Mevion Medical Systems have conducted 
research studying FLASH irradiation, which can deliver 200 Gy/s average dose rate 
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at the Bragg peak and has potential in achieving higher tumor control rates than 
previously reported [32]. Collaborations between vendors and proton facilitates 
not only has potential for advances in research but facilitates the incorporation of 
clinical considerations into improvements in technology and treatment delivery.
4. Cost
In addition to space requirements, another major factor for health systems to 
consider in the implementation of a proton therapy center is the financial burden. 
The cost of the construction, equipment, technological considerations and staffing 
must all be taken into account. Although proton therapy has demonstrated more 
favorable dose distributions when compared to photon therapy [21], determining 
specific patients within a department of radiation oncology who are most likely to 
benefit may be a challenge. Moreover, it may also be helpful for health systems to 
consider the vicinity of other proton therapy centers and how this might affect their 
patient base.
Proton therapy centers have been reported to cost up to 235 million USD [33]. 
However, since vendors have developed technology that substantially reduces 
footprint, this has led to more feasible costs for health systems. Of course, this is 
dependent on the size of the facility, number of treatment rooms as well as if they 
are fixed-beam or gantry. In more recent years, proton therapy centers have been 
reported to cost closer to 25 million USD, which makes the cost/benefit analysis 
more reasonable for health systems. Perhaps not surprisingly, proton treatments 
have been reported to cost more than photon treatments [33], and this should 
also be considered when assessing facility returns and navigating the insurance 
process.
5. Faculty and staff considerations
Optimal efficiency of a proton therapy facility is dependent on an expert staff 
and smooth transition for patients during each aspect of their treatment (check-in, 
waiting area, consult rooms, on-treatment visit (OTV) rooms, simulation, mold 
preparation, and guidance to a treatment room being used for a patient’s specific 
condition). Due to the generally large space of a proton center and the technical 
complexities it requires, having well-trained faculty and staff is imperative for 
execution of day-to-day operations. This includes physicians, physicists, dosime-
trists, radiation therapists, radiation oncology nurses, machinists, operations 
engineers and administrative staff. The number of faculty and staff at a given time 
will depend on the size of the facility, number of patients being treated and quality 
assurance protocols for the specific equipment being used.
As photon therapy delivery requires specific training and experience, this is also 
the case with proton therapy. However, several potential challenges, which include 
the intricate details of proton therapy and lack of experience by faculty and staff 
predominately trained in photon techniques may result in a new proton center 
encountering delays and issues when it treats its initial set of patients. To minimize 
these potential issues, it may be helpful for radiation oncology departments who 
plan to construct a proton center to encourage faculty and staff to enroll in courses 
to familiarize themselves with the technical details and workflow. Organizations 
including the Particle Therapy Co-Operative Group and European Society for 
Radiotherapy and Oncology as well as institutions including the University of 
Pennsylvania, University of Texas MD Anderson Cancer Center and Mayo Clinic 
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have offered courses, seminars and workshops to educate those who plan to or are 
currently involved in administering proton therapy.
6. Conclusion and future directions
As proton therapy evolves and become more prevalent, advances in facility 
design and treatment delivery are likely to continue that will make it more feasible 
for health systems to consider adopting. Vendors have responded by developing 
more affordable systems that reduce footprint while offering flexibility in number 
of fixed-beam or gantry treatment rooms. Pencil-beam scanning and variations in 
gantry angle are other advances that have shown considerable promise. Together, 
when also considering the favorable dose distributions of proton therapy, it is likely 
that the number of institutions offering proton therapy will continue to rise.
Going forward, it is critical that proton therapy facilities, vendors and physicists 
and engineers in both academia and the private sector continue to form collabora-
tions that improve treatment delivery and imaging technology while reducing foot-
print. As proton therapy facilities gain more experience by treating larger numbers of 
patients, the knowledge they acquire should be relayed to vendors in order to improve 
patient care, develop more effective equipment and maintain a high-standard of 
quality assurance. Vendors should continue to have smooth processes that replace or 
upgrade outdated equipment. As always, questions and ideas should continue to be 
shared in society meetings, educational sessions and other forums.
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